Sanofi (SNY) Cut to Sell at BidaskClub

BidaskClub cut shares of Sanofi (NYSE:SNY) from a hold rating to a sell rating in a research note released on Monday, July 24th.

A number of other equities research analysts have also recently commented on SNY. J P Morgan Chase & Co reiterated a sell rating on shares of Sanofi in a report on Thursday, March 30th. Argus started coverage on Sanofi in a report on Thursday, April 6th. They set a buy rating and a $50.00 price objective on the stock. HSBC Holdings plc cut Sanofi from a hold rating to a reduce rating in a report on Friday, April 7th. Zacks Investment Research raised Sanofi from a hold rating to a buy rating and set a $50.00 target price on the stock in a research report on Tuesday, April 11th. Finally, TheStreet raised Sanofi from a c+ rating to a b- rating in a research report on Monday, April 24th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the stock. Sanofi has an average rating of Hold and a consensus target price of $63.75.

Sanofi (NYSE:SNY) traded up 0.84% during mid-day trading on Monday, reaching $48.08. The company had a trading volume of 1,172,670 shares. Sanofi has a 52 week low of $36.81 and a 52 week high of $50.24. The stock has a 50 day moving average of $48.11 and a 200 day moving average of $45.82. The stock has a market capitalization of $121.39 billion, a price-to-earnings ratio of 11.54 and a beta of 0.88.

Sanofi (NYSE:SNY) last announced its earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting analysts’ consensus estimates of $0.74. The firm had revenue of $8.66 billion for the quarter, compared to analysts’ expectations of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The business’s revenue for the quarter was down 2.3% on a year-over-year basis. Analysts anticipate that Sanofi will post $3.23 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “[[title]]” was first reported by [[site]] and is owned by of [[site]]. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at [[permalink]].

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Harbour Capital Advisors LLC purchased a new position in Sanofi during the first quarter valued at $113,000. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock valued at $171,000 after buying an additional 3,713 shares during the last quarter. Proficio Capital Partners LLC boosted its position in Sanofi by 95.8% in the first quarter. Proficio Capital Partners LLC now owns 4,265 shares of the company’s stock valued at $210,000 after buying an additional 2,087 shares in the last quarter. Huntington National Bank raised its stake in Sanofi by 3.4% in the first quarter. Huntington National Bank now owns 4,455 shares of the company’s stock valued at $202,000 after buying an additional 147 shares during the last quarter. Finally, BLB&B Advisors LLC acquired a new stake in Sanofi during the first quarter valued at about $202,000. 9.97% of the stock is currently owned by institutional investors.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.